{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.9","upperLimit":"87.2","value":"85.0"},{"groupId":"OG001","lowerLimit":"83.3","upperLimit":"87.8","value":"85.5"},{"groupId":"OG002","lowerLimit":"83.5","upperLimit":"87.8","value":"85.7"}]}],"title":"Baseline (n=344,355,344)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.2","upperLimit":"1.0","value":"-1.6"},{"groupId":"OG001","lowerLimit":"0.4","upperLimit":"4.2","value":"2.3"},{"groupId":"OG002","lowerLimit":"-2.1","upperLimit":"1.6","value":"-0.2"}]}],"title":"Change From Baseline at Cycle 7 (n=261,252,261)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"365"},{"groupId":"OG001","value":"367"},{"groupId":"OG002","value":"363"}],"units":"Participants"}],"description":"The RSCL is a self-reported instrument which consists of 4 domains including physical symptom distress, psychological distress, activity level, and overall global life quality. Only the activity level scale was collected and assessed. Scores may range from 0 to 100, with higher scores indicating increased burden of disease. Mean RSCL activity scale score changes were calculated as \\[mean score at the assessment visit minus mean score at Baseline\\]. The higher the score, the higher the level of impairment or burden.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received trastuzumab plus either docetaxel or paclitaxel. The regimen was chosen at the investigator's discretion. Option 1: trastuzumab 8 mg/kg via IV infusion on Day 1 of Cycle 1, then 6 mg/kg IV on Day 1 of each subsequent 3-week cycle; plus a minimum of 6 cycles with docetaxel 75 or 100 mg/m\\^2 IV on Day 1 of each 3-week cycle. Option 2: trastuzumab 4 mg/kg IV on Day 1 of Cycle 1, then 2 mg/kg IV weekly beginning on Day 8 of Cycle 1; plus a minimum of 18 weeks with paclitaxel 80 mg/m\\^2 IV weekly. Treatment continued until disease progression, unacceptable toxicity, or study termination. If trastuzumab or docetaxel were discontinued for toxicity, the other agent could be continued as monotherapy.","id":"OG000","title":"Trastuzumab + Taxane"},{"description":"Participants received trastuzumab emtansine plus pertuzumab-placebo. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the placebo IV infusion, on Day 1 of each 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.","id":"OG001","title":"Trastuzumab Emtansine + Placebo"},{"description":"Participants received trastuzumab emtansine plus pertuzumab. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the pertuzumab IV infusion, on Day 1 of each 3-week cycle. Pertuzumab was given as 840 mg IV on Day 1 of Cycle 1, then 420 mg IV on Day 1 of each subsequent 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.","id":"OG002","title":"Trastuzumab Emtansine + Pertuzumab"}],"paramType":"MEAN","populationDescription":"ITT Population. Here, 'n' signifies the number of participants with available data at baseline and Cycle 7 (Week 18).","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 7 (Week 18)","title":"Change From Baseline in Rotterdam Symptom Checklist (RSCL) Activity Level Scale Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}